Literature DB >> 16046037

Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.

A D Cox1, W Zou, M A J Gidney, S Lacelle, J S Plested, K Makepeace, J C Wright, P A Coull, E R Moxon, J C Richards.   

Abstract

Glycoconjugates were prepared by covalently linking the immunogenic protein carrier CRM(197) to O-deacylated lipopolysaccharide (LPS) derived from Neisseria meningitidis (strain H44/76), immunotype L3 galE LPS. This mutant strain elaborates a truncated LPS structure that displays immunological epitopes characteristic of 76% of Group B meningococcal (NmB) strains. CRM(197) was covalently linked either to the reducing glucosamine residue of the lipid A region of the O-deacylated LPS or to a 2-keto-3-deoxy-octulosonic acid (Kdo) residue in the inner core region of the O-deacylated LPS. In both rabbits and mice a much stronger IgG response to the immunising antigen was generated in those animals that received conjugates linked via the lipid A region. Sera from mice that were immunized with these conjugates were assayed for their reactivity with LPS, both mutant and wild-type, of several homologous and heterologous NmB strains. Sera obtained from mice immunized with conjugates in which the carrier protein was linked via the Kdo moiety were only able to react with O-deacylated, but not fully acylated (native), LPS from the homologous strain. However, sera obtained from mice that were immunized with conjugates, in which the carrier protein was coupled to the lipid A region, reacted predominately with inner core epitopes that contained phosphoethanolamine at the same 3-position of the distal heptose residue (HepII) of the inner core LPS as was present on the immunising antigen. Additionally it was observed that sera from rabbits immunised with lipid A linked conjugates, unlike the mice responses, were generally not as specific for LPS antigens that contained phosphoethanolamine at the same 3-position as was present on the immunising antigen, but showed a broader inner core recognition, whereas those rabbits that received the Kdo-linked conjugates gave only a very weak non-specific response to all immunotypes. Finally, the sera from two out of six mice that had received lipid A linked conjugates had bactericidal activity against L3 wild-type NmB strain 8047 and one of these was able to passively protect against meningococcal infection in an infant rat model. This study demonstrates evidence towards the proof-in-principle that by using Nm inner core LPS conjugates coupled via the lipid A region with an intact phosphoethanolamine at the O-3 position of the HepII of the inner core LPS, it is possible to elicit functional and protective antibodies against meningococcal infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046037     DOI: 10.1016/j.vaccine.2005.06.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading.

Authors:  Andrew D Cox; Frank St Michael; Dhamodharan Neelamegan; Suzanne Lacelle; Chantelle M Cairns; Marzia M Giuliani; Alessia Biolchi; J Claire Hoe; E Richard Moxon; James C Richards
Journal:  Glycoconj J       Date:  2010-10-05       Impact factor: 2.916

2.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading.

Authors:  Andrew D Cox; Frank St Michael; Dhamodharan Neelamegan; Suzanne Lacelle; Chantelle Cairns; James C Richards
Journal:  Glycoconj J       Date:  2010-03-26       Impact factor: 2.916

4.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

5.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides.

Authors:  F St Michael; C M Cairns; A L Filion; A Biolchi; B Brunelli; M Giuliani; J C Richards; A D Cox
Journal:  Glycoconj J       Date:  2013-09-07       Impact factor: 2.916

6.  Investigating the candidacy of lipopolysaccharide-based glycoconjugates as vaccines to combat Mannheimia haemolytica.

Authors:  Frank St Michael; Chantelle Cairns; Amy Lea Filion; Dhamodharan Neelamegan; Suzanne Lacelle; Andrew D Cox
Journal:  Glycoconj J       Date:  2011-06-24       Impact factor: 2.916

7.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

Review 8.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

9.  Neisseria meningitidis escape from the bactericidal activity of a monoclonal antibody is mediated by phase variation of lgtG and enhanced by a mutator phenotype.

Authors:  Christopher D Bayliss; J Claire Hoe; Katherine Makepeace; Patricia Martin; Derek W Hood; E Richard Moxon
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

10.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Gil Ben-Menachem; Vince Pozsgay; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2008-05-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.